

Nafith Abu Tarboush  
DDS, MSc, PhD  
natarboush@ju.edu.jo  
[www.facebook.com/natarboush](http://www.facebook.com/natarboush)

# Obesity



# Obesity



- A disorder affecting body weight regulatory systems
- Characterized by an accumulation of excess body fat
- Primitive societies vs. developed ones! (availability & activity)
- Prevalence increases with age
- Risk of associated diseases (diabetes, hypertension, cardiovascular disease)
- Childhood obesity: three fold increase in prevalence over the last four decades
- In fact, there are more obese than undernourished individuals worldwide

# Statistics

- Approximately 17% of those age 2–19 years are obese
- In USA:
  - Lifetime risk of becoming overweight ~ 50%
  - Lifetime risk of becoming obese is ~ 25%
- Worldwide: 650,000,000 - WHO 2016
- Jordan: 2,800,000 - WHO 2016



# Assessment of Obesity

- 1. **Body mass index**: (exceptions - athletes)
- A measure of relative weight, adjusted for height
- Allows comparisons both within & between populations
- $BMI = (\text{weight in kg}) / (\text{height in meters})^2$
- Healthy = 18.5-24.9; Overweight = 25-29.9; Obese =  $\geq 30$ ; morbidly obese  $> 40$
- $\approx 2/3$  of American adults are overweight &  $> 36\%$  are obese



# Assessment of Obesity



- 2. **Waist circumference**:  $\geq 40$  in (2.54cm) (men) and  $\geq 35$  in (women)
- 3. Anatomic differences in fat deposition (**W/H ratio**)
- Android, "apple-shaped," or upper body obesity: excess fat located in the central abdominal area
  - Associated with a greater risk for hypertension, insulin resistance, diabetes, dyslipidemia, & coronary heart disease
  - Waist to hip ratio:  $> 0.8$  for women &  $> 1.0$  for men





# Assessment of Obesity

- Gynoid, “pear-shaped,” or lower body obesity: fat distributed in the lower extremities around the hips or gluteal region
  - Waist to hip ratio:  $< 0.8$  for women &  $< 1.0$  for men
  - Relatively benign health wise
  - Commonly found in females




# Assessment of Obesity

- Biochemical differences in regional fat depots


## A. Abdominal fat:

- Cells are much larger
- Higher rate of fat turnover
- Hormonally more responsive
- Readily mobilizable: men lose weight more readily than women
- Portal vein: fatty acids may lead to insulin resistance & increased synthesis of triacylglycerols, which are released as very-low-density lipoprotein (VLDL)



# Assessment of Obesity


- Biochemical differences in regional fat depots
- B.** Gluteal fat: fatty acids from gluteal fat enter the general circulation, & have no preferential action on hepatic metabolism





# Assessment of Obesity



- Number of fat cells
- The ability of a fat cell to expand is limited (2-3 folds)
- Fat cells, once gained, are never lost! (10 years cycle)
- Formerly obese patients have a particularly difficult time maintaining their reduced body weight



# Body Weight Regulation

*Body weight is stable as long as the behavioral & environmental factors that influence energy balance are constant*

# The concept of a set point! – not a 100%



# A. Genetic contributions to obesity


- Uncontrolled, greedy eating behavior
- Genetic mechanisms play a major role in body weight (rather than a lack of willpower)
- Often observed clustered in families
- 80% when parents fat, 9% when parents are lean
- Inheritance is not simple mendelian genetics (a complex polygenic disease)
- Adopted children usually correlates with biologic parents
- Identical twins have very similar BMI





# B. Environmental & behavioral contributions

- The epidemic of obesity occurring over the last four decades! genetic factors are stable on this short time scale
- Environmental & behavioral:
  - Ready available food
  - Energy-dense food
  - Sedentary lifestyles: TV, cars, computer (energy-sparing)
  - Eating behaviors: snacking, portion size, number of people
- Men in Japan (aged 46–49 years) are lean (BMI = 20), in California (BMI = 24)







# Molecules that Influence Obesity

Obesity results when energy intake exceeds energy expenditure

---


# Molecular influences




# Long Term Signals



- Reflect the status of fat (TAG) stores
- 1. Leptin: Structure, product of ob gene, Produced proportionally to the adipose mass, Informs the brain of the fat store level, Regulate body fat through the control of appetite & energy expenditure (an anorexigenic effect)
  - Daily injection of leptin in mice
  - Plasma leptin in obese humans is usually normal for their fat mass (resistance to leptin rather than deficiency)





# Long Term Signals

- 2. Insulin:
  - Obese individuals are also hyperinsulinemic
  - Like leptin, insulin acts on hypothalamic neurons to decrease appetite
  - Obesity is associated with insulin resistance



# Short Term Signals

- From the GI tract (control hunger and satiety)
- Affect size and number of meals (over minutes to hours)
- In the absence of food intake (between meals)
  - Stomach produces ghrelin – orexigenic (appetite-stimulating)
- As food is consumed
  - GI hormones (CCK and peptide YY, ...) induce satiety (an anorexigenic effect) → terminating eating

# Short Term Signals

- Within the hypothalamus
  - Neuropeptides (such as orexigenic neuropeptide Y [NPY]) and anorexigenic  $\alpha$ -MSH and neurotransmitters (such as serotonin and dopamine) are important in regulating hunger and satiety
- Long-term and short-term signals interact
  - Leptin increases secretion of  $\alpha$ -MSH and decreases secretion of NPY
  - There are many **complex regulatory loops** that control the **size and number** of meals in relationship to the status of body fat stores
- $\alpha$ -MSH (proopiomelanocortin)  $\rightarrow$  (MC<sub>4</sub>R)
  - Loss-of-function mutations to MC<sub>4</sub>R are associated with early-onset obesity

# Metabolic Changes Observed in Obesity

- Metabolic syndrome (insulin resistance syndrome, syndrome X)
  - Glucose intolerance, Insulin resistance, Hyperinsulinemia
  - Dyslipidemia (low HDL & high VLDL)
  - Hypertension
- Increased risk for diabetes mellitus & cardiovascular disorders (men: 4 times higher mortality of cardiovascular disease)


Metabolic syndrome  
(Syndrome X)

- Central obesity
- High blood pressure
- High triglycerides
- Low HDL-cholesterol
- Insulin resistance




# Metabolic Changes Observed in Obesity

- Insulin resistance causes increased activity of hormone-sensitive lipase, resulting in increased levels of circulating fatty acids
- In liver converted to triacylglycerol and cholesterol
- Released as VLDL, resulting in elevated serum triacylglycerols
- Concomitantly, HDL levels are decreased



# Obesity and Health


- Correlated with increased risk of death
- Risk factor for:
  - Adult onset diabetes;
  - Hypercholesterolemia;
  - High plasma TAGs;
  - Hypertension; Heart disease; some Cancers;
  - Gallstones; Arthritis;
  - Gout
- The relationship is stronger for <55 yrs
- After age 74, there is no association between increased BMI & mortality






# Weight Reduction

- Physical activity
- Create an energy deficit
- Increases cardiorespiratory fitness
- Combine caloric restriction & exercise with behavioral treatment may lose about 5–10% of body weight over a period of 4–6 months



# Weight Reduction


- Caloric restriction
- The most common approach
- 1 pound (454 gm) of adipose tissue corresponds to approximately 3,500 kcal
- Ineffective over the long term for many individuals





# Weight Reduction

- Pharmacologic & surgical treatment
- Two medications (BMI  $\geq 30$ ):
  - Sibutramine: appetite suppressant that inhibits the reuptake of both serotonin & norepinephrine
  - Orlistat: lipase inhibitor that inhibits gastric and pancreatic lipases



# Weight Reduction

- Surgical procedures are an option for the severely obese patients
- Surgery produces greater & more sustained weight loss than dietary or pharmacologic therapy, but has substantial risks for complications

